Next-generation HIF-2α inhibitor shows promise in kidney cancer translational clinical trial

The first-in-patient, single-arm ARC-20 clinical trial, led by Dana-Farber Cancer Institute's Toni K.

Choueiri, MD, has evaluated casdatifan, a next-generation HIF-2α inhibitor, as monotherapy for metastatic clear cell renal cell carcinoma (ccRCC), the most common subtype of kidney cancer.

Patients eligible for the study were previously treated with standard therapies. ...